Anti-Human CD19 & CD3E Bispecific Reference Antibody (Blinatumomab, RUO)

Description: Blinatumomab (BS10596) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Mouse
Isotype: (scFv-kappa-heavy)-(scFv-heavy-kappa)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 30 mM Histidine, pH5.8, 10% Sucrose, 0.02% Tween80.
Concentration: 1.74mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD19,DifferentiationantigenCD19,T-cellsurfaceantigenLeu-12,B-lymphocyteantigenCD19,B-lymphocytesurfaceantigenB4,T3E,T-cellsurfaceantigenT3/Leu-4epsilonchain,CD3e,CD3E,T-cellsurfaceglycoproteinCD3epsilonchain
Purification: Purified by Nickel column.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,CD19,AMG103,BITEMT-103,MEDI-538,MT103,bscCD19xCD3,CAS:853426-35-4
Background: Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.
Note: For research use only. Not suitable for clinical or therapeutic use.